This is the authors' abstract. We don't add key points for this paper.
In a retrospective Nigerian cohort of 33 982 people with HIV-1 initiating or switching to tenofovir, lamivudine, and dolutegravir, virological suppression reached 80%-82% among participants with available viral load data and 63%-65% by intention-to-treat analysis. Suppression was higher among switchers, while age and gender predicted suppression.
Answers are grounded in this paper and cite their sources.
No takes yet. Share an insight, caveat, or question.
Abdullahi et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: